TD Cowen Reiterates Buy Rating on Jazz Pharmaceuticals (JAZZ)

TD Cowen analyst Joseph Thome, Ph.D reiterated a Buy rating and $200.00 price target on Jazz Pharmaceuticals (NASDAQ: JAZZ).

The analyst commented, "The Ph. III study of Epidiolex in Japan did not meet its primary endpoint, though Jazz did see improvements on several measures, and believes the data could still support advancement in JP. While a disappointment, we did not have Epidiolex revenues from the region in our model, and our estimates remain unchanged. We continue to see JAZZ as undervalued for the company's currently marketed products."

For an analyst ratings summary and ratings history on Jazz Pharmaceuticals click here. For more ratings news on Jazz Pharmaceuticals click here.

Shares of Jazz Pharmaceuticals closed at $114.55 yesterday.

You May Also Be Interested In

• Emkay Global Starts Urban Company (URBANCO:IN) at Buy (1)
• Lazard Global Total Return fund declares $0.1534 monthly distribution
• BofA says CTA Treasury shorts stable, euro short-cover risk rises